Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ALNY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ALNY

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Alnylam Pharmaceuticals Inc

ALNY
Current price
314.94 USD -7.7 USD (-2.39%)
Last closed 322.64 USD
ISIN US02043Q1076
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 42 300 686 336 USD
Yield for 12 month +22.94 %
1Y
3Y
5Y
10Y
15Y
ALNY
21.11.2021 - 28.11.2021

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Address: 675 West Kendall Street, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

325.06 USD

P/E Ratio

Dividend Yield

Financials ALNY

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ALNY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+2 248 243 000 USD

Last Year

+1 828 292 000 USD

Current Quarter

+594 189 000 USD

Last Quarter

+593 166 000 USD

Current Year

+1 924 873 000 USD

Last Year

+1 517 886 000 USD

Current Quarter

+523 148 000 USD

Last Quarter

+490 349 000 USD
EBITDA -57 815 000 USD
Operating Margin TTM 3.04 %
Price to Earnings
Return On Assets TTM -1.79 %
PEG Ratio -0.49
Return On Equity TTM -1 500.66 %
Wall Street Target Price 325.06 USD
Revenue TTM 2 348 099 072 USD
Book Value 0.89 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 20.20 %
Dividend Yield
Gross Profit TTM 2 019 664 000 USD
Earnings per share -2.09 USD
Diluted Eps TTM -2.09 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -11.49 %

Stock Valuation ALNY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 2 000.00
Enterprise Value Revenue 17.25
Price Sales TTM 18.01
Enterprise Value EBITDA 204.85
Price Book MRQ 362.44

Technical Indicators ALNY

For 52 Weeks

205.87 USD 333.70 USD
50 Day MA 296.86 USD
Shares Short Prior Month 3 375 720
200 Day MA 267.95 USD
Short Ratio 3.72
Shares Short 3 327 381
Short Percent 3.42 %